Drugs / CH505 w24 mRNA-gp160
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07757802 | Oct 2026 → Jun 2028 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CH505 w24 mRNA-gp160 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07757802 ↗ |
| Modality | Messenger RNA (mRNA) | “CH505 HIV-1 envelope mRNA vaccine” NCT07757802 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT07757802 ↗ |